La chaîne d'options affiche les données clés des options sur actions de HCW Biologics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour HCW Biologics..

HCW Biologics (NASDAQ:HCWB) Stock, Chaîne d'Options

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

HCW Biologics Inc

News

Management

AMD Announces Darla Smith Resigns As Chief Accounting Officer, To Remain VP Until January 2025; Philip Carter Appointed As New Chief Accounting Officer

GBDC

Golub Capital BDC Reveals Series Of Debt Funding Structure Initiatives Expected To Reduce  Prospective Borrowing Costs And Provide Investment Flexibility

Investors and speculators are gearing up for Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) earnings report on Wednesday, an event that&#8217;s expected to send ripples, if not tidal waves, <a href="https://www.benzinga.com/markets">across the U.S. stock market. </a>
If the options market is right, Nvidia's results could spark moves in the S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – larger than those typically triggered by key economic data like the employment and inflation reports.
Nvidia's dominance in the AI-driven technology trade has turned its earnings into a barometer for overall market sentiment, and its influence on the stock market is unparalleled.
Over the past year, Nvidia accounted for 20% of the S&amp;P 500's total returns and Bank of America's derivatives analyst Gonzalo Asis didn't mince words: &#8220;It remains the most dominant stock in the market… expected to drive nearly 25% of the S&amp;P 500&#8217;s EPS growth in 3Q.&#8221;
In essence, whether Nvidia beats or misses expectations, the ripple effects will likely extend far beyond its ticker.
<h3 class="wp-block-heading">S&amp;P 500 Implied Move Is Higher Than Inflation Or Jobs Data</h3>
The options market implies a potential 1.05% move in the S&amp;P 500—higher than what traders expect from next month's Non-Farm Payroll (NFP) data, Consumer Price Index (CPI) print, and in line with the Federal Reserve&#8217;s December meeting.
&#8220;Options are assigning more broad-market risk around NVDA earnings than around next month&#8217;s NFP and CPI days, and as much as the Dec FOMC,&#8221; the analyst noted.
For Nvidia shares themselves, the implied one-day move is even more eye-popping: 12.5%.
&#8220;We remain cautious of fragility risks in single names around earnings, but NVDA hedges themselves are not particularly cheap relative to how much the stock has reacted to results in the last two years,&#8221; Assis wrote.
The analyst also warned that the recent easing of post-election euphoria and heightened single-stock fragility can be reasons for traders to hedge against potential market turbulence if Nvidia disappoints.
<h3 class="wp-block-heading">A Strategy For Hedging The Nasdaq Impact</h3>
For traders seeking to hedge the broader market risks tied to Nvidia&#8217;s performance, Bank of America recommended an option strategy using put spreads on the Nasdaq-100 ETF, the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>). Specifically, the QQQ 22Nov 490-480 put spreads are priced at $2 and could offer a 5x payout if the Nasdaq-100 falls by roughly 3.3% this week.
Despite the potential need for hedges, the bank also noted that hedging NVDA earnings directly is not cheap, considering how significantly the stock has reacted to its last few earnings reports.
<h3 class="wp-block-heading">Historical Nvidia Earnings Data</h3>
Data from <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1">Benzinga Pro</a> shows that over the last 12 quarters, Nvidia has exceeded earnings-per-share (EPS) expectations 10 times and missed revenue expectations only once. 
On average, Nvidia shares moved 5.3% in the single trading day following its earnings release.
The largest 1-day gain followed its first quarter 2024 earnings, when the stock surged 24.4%, while the worst reaction occurred after fourth quarter 2024 results, with a decline of 7.6%. 
Here's a snapshot of the company's recent earnings performance:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Fiscal Quarter</th>
<th>Date Announced</th>
<th>Surprise % EPS</th>
<th>Surprise % Revenue</th>
<th>1-Day % NVDA Move</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2-2025</td>
<td>8/28/24</td>
<td>6.25%</td>
<td>4.73%</td>
<td>-6.38%</td>
</tr>
<tr>
<td>Q1-2025</td>
<td>5/22/24</td>
<td>2.86%</td>
<td>5.66%</td>
<td>9.32%</td>
</tr>
<tr>
<td>Q4-2024</td>
<td>2/21/24</td>
<td>11.45%</td>
<td>7.19%</td>
<td>16.40%</td>
</tr>
<tr>
<td>Q3-2024</td>
<td>11/21/23</td>
<td>19.64%</td>
<td>12.39%</td>
<td>-2.46%</td>
</tr>
<tr>
<td>Q2-2024</td>
<td>8/23/23</td>
<td>29.19%</td>
<td>20.38%</td>
<td>0.10%</td>
</tr>
<tr>
<td>Q1-2024</td>
<td>5/24/23</td>
<td>18.48%</td>
<td>10.31%</td>
<td>24.37%</td>
</tr>
<tr>
<td>Q4-2023</td>
<td>2/22/23</td>
<td>8.64%</td>
<td>0.68%</td>
<td>14.02%</td>
</tr>
<tr>
<td>Q3-2023</td>
<td>11/16/22</td>
<td>-15.94%</td>
<td>2.79%</td>
<td>-1.46%</td>
</tr>
<tr>
<td>Q2-2023</td>
<td>8/24/22</td>
<td>-59.20%</td>
<td>-17.23%</td>
<td>4.01%</td>
</tr>
<tr>
<td>Q1-2023</td>
<td>5/25/22</td>
<td>5.43%</td>
<td>2.07%</td>
<td>5.16%</td>
</tr>
<tr>
<td>Q4-2022</td>
<td>2/16/22</td>
<td>8.20%</td>
<td>3.01%</td>
<td>-7.56%</td>
</tr>
<tr>
<td>Q3-2022</td>
<td>11/17/21</td>
<td>6.36%</td>
<td>4.00%</td>
<td>8.25%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: Benzinga Pro</figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">Inflation Could Surge To 3% If Trump Applies Universal Tariffs: Goldman Sachs</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Equities

Broad U.S. Equity ETFs

Previews

Options

Econ #s

Economics

Federal Reserve

Tech

ETFs

NVDA

Why Nvidia Earnings May Trigger Massive S&P 500 Volatility

Current CEO Lou Haddad will retire at the end of 2024 but will retain the role of Executive Chairman of the Company's Board of Directors. Additionally, the Board of Directors expects to appoint Tibbetts to the Board of Directors upon his elevation to Chief Executive Officer.

Armada Hoffler Names Shawn Tibbetts As CEO, Effective January 1, 2025; Current CEO Lou Haddad To Retain The Role Of Executive Chairman

-The New York Stock Exchange ("NYSE", the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Spirit Airlines, Inc. (the "Company") — ticker symbol SAVE — from the NYSE. Trading in the Company's common stock will be suspended immediately.
NYSE Regulation reached its decision that the Company is no longer suitable for listing pursuant to NYSE Listed Company Manual Section 802.01D after the Company's November 18, 2024 press release and Form 8-K disclosures that the Company has commenced a prearranged chapter 11 process in the United States Bankruptcy Court for the Southern District of New York. In reaching its delisting determination, NYSE Regulation notes the Company disclosed that all of the Company's existing common stock and other equity interests will be cancelled without any distributions to the holders of such common stock and other equity interests on account thereof.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

SAVE

NYSE To Commence Delisting Proceedings Against Spirit Airlines, Effective Immediately

Guidance

Healthpeak Properties Raises FY24 AFFO From $1.56-$1.58 To $1.57-$1.59

MCHP

Microchip Technology Announces Ganesh Moorthy Is Retiring As CEO, President And Board Member; Steve Sanghi Appointed Interim CEO

Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30.0 million of shares of common stock at the public offering price, less the underwriting discount. All of the shares of common stock and pre-funded warrants in the offering will be sold by Spyre.&nbsp;
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC, Goldman Sachs &amp; Co. LLC, Evercore Group L.L.C., and Guggenheim Securities, LLC are acting as the joint book-running managers for the proposed offering. LifeSci Capital LLC is acting as lead manager for the proposed offering.

Offerings

SYRE

Spyre Therapeutics Announces Proposed $200M Public Offering Of Its Common Stock And Pre-Funded Warrants

WIIM

OMCL

Omnicell shares are trading lower after the company announced a proposed private placement of $150 million in convertible senior notes.

Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) ("Omnicell") today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes.
The notes will be general unsecured, senior obligations of Omnicell, will accrue interest payable semiannually in arrears and will mature on December 1, 2029, unless earlier converted, redeemed or repurchased. Upon conversion, Omnicell will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Omnicell's common stock or a combination of cash and shares of Omnicell's common stock, at Omnicell's election, in respect of the remainder, if any, of Omnicell's conversion obligation in excess of the aggregate principal amount of the notes being converted. The interest rate, initial conversion rate, redemption or repurchase rights and other terms of the notes will be determined at the time of pricing of the offering.

Omnicell Announces Proposed Private Placement Of $150M Of Convertible Senior Notes Due 2029

Donald Trump was viewed as the more pro-cryptocurrency presidential candidate in the 2024 election and his support for crypto could get another push with a report that his media company is acquiring a<a href="https://www.benzinga.com/markets/cryptocurrency/21/01/19071375/spac-surges-64-on-report-of-merger-talks-with-ice-owned-crypto-exchange-bakkt"> cryptocurrency trading company.</a>
What Happened: Shares of Bakkt Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NASDAQ">BKKT</a>) are soaring Monday on reports the cryptocurrency company, <a href="https://www.benzinga.com/markets/cryptocurrency/21/04/20550003/3-cryptocurrency-spacs-that-could-run-on-a-successful-coinbase-ipo">which went public </a>in October 2021 via SPAC merger, is being acquired by Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>).
The media company co-founded by Trump, which owns the Truth Social platform, is in advanced talks to acquire Bakkt, <a href="https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f">according </a>to the Financial Times. The report said Trump Media &amp; Technology Group would acquire the cryptocurrency company, which is backed by Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), in an all-share deal.
Benzinga reached out to Trump Media &amp; Technology Group for comment on the report and will update the story accordingly. Benzinga has also contacted Bakkt for comment. 
Bakkt's first CEO was Kelly Loeffler, who was previously a member of the U.S. Senate, representing the state of Georgia as a Republican. Loeffler is helping to organize Trump's inauguration in January and has close ties to the president-elect.
The Intercontinental Exchange, which owns the New York Stock Exchange, owns a reported 55% of Bakkt. The exchange company would have to give approval to any such sale to the Trump media company.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Bakkt <a href="https://www.benzinga.com/news/24/06/39234822/bakkt-holdings-explores-potential-sale-or-breakup-amid-crypto-sector-consolidation">said in June</a> it was exploring strategic alternatives that could include a sale or breakup of the company.
The company previously said its crypto custody business could be wound down. This segment might not be included in the buyout, according to the report. Bakkt is planning to build a crypto trading platform geared to institutional investors.
DJT shares have experienced high volatility and an increased valuation after Trump won the 2024 election.
Trump's <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41096120/if-you-invested-1-000-in-bitcoin-when-donald-trump-said-he-wasnt-a-fan-heres-how-much-youd">pro-crypto stance</a> may have helped elevate Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies to all-time highs following his <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">2024 election win.</a>
An acquisition of Bakkt would push Trump's media company and the president-elect deeper into the cryptocurrency sector, which comes after he promoted a crypto venture called World Liberty Financial with business partners.
BKKT, DJT Price Action: Bakkt stock was halted several times after the report and ended Monday&#8217;s session 163.04% higher at $29.71 versus a 52-week trading range of $5.57 to $68.75. Bakkt shares are down 44% year-to-date in 2024.
Trump Media &amp; Technology stock is up 16.65% to $32.78 Monday versus a 52-week trading range of $22.55 to $79.38. Trump Media &amp; Technology stock is up 85% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41760961/djt-stock-volatile-on-election-day-donald-trumps-media-company-reports-q3-earnings-growth-initiativ">DJT Stock Volatile On Election Day: Donald Trump&#8217;s Media Company Reports Q3 Earnings, Growth Initiatives</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Social Media

Politics

Movers

Trading Ideas

$BTC

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Trump Digs Deeper Into Cryptocurrency? Bakkt Shares Soar On Reported Interest From President-Elect's Media Company

The consolidation of the Company's welded wire manufacturing operations is expected to result in the elimination of up to 35 positions at the Warren facility. It is anticipated that operations at the Warren facility will cease by the end of November 2024. Insteel expects to incur a restructuring charge of approximately $1.9 million related to the facility's closure.

IIIN

Insteel Industries Plans Closing Its Facility In Warren, Ohio; Resulting In Elimination Of Up To 35 Positions; Expects To Incur Restructuring Charge Of $1.9M

Fiscal 2025 Financial Guidance
<ul>
<li>AECOM expects to deliver record net service revenue and profitability, margins and continued strong cash flow conversion, including:
<ul>
<li>Organic NSR2 growth of 5% to 8%.
<ul>
<li>Expect phasing to follow a normal seasonal pattern with accelerating growth as the year progresses.</li>
</ul>
</li>
<li>Adjusted1 EBITDA4 of between $1,170 million and $1,210 million, reflecting an increase of 9% at the mid-point over fiscal 2024.</li>
<li>An adjusted EBITDA margin5 of 16.3%, representing a 30 basis point increase from fiscal 2024.</li>
<li>Adjusted1 EPS of between $5.00 and $5.20, reflecting an increase of 13% at the mid-point compared to fiscal 2024.</li>
<li>100%+ free cash flow6 conversion.</li>
</ul>
</li>
<li>Other assumptions incorporated into guidance:
<ul>
<li>An average fully diluted share count of 134 million, which reflects only shares repurchased to-date, though the Company intends to continue repurchasing stock that would provide a benefit to per share earnings.</li>
<li>An adjusted effective tax rate of approximately 24% for the full year.
<ul>
<li>The Company expects to maintain an approximately 24% tax rate for the next several years.</li>
</ul>
</li>
</ul>
</li>
<li>See the Regulation G Information tables at the end of this release for a reconciliation of non-GAAP measures to the most directly comparable GAAP measures.</li>
</ul>
Long-Term Financial Framework for Value Creation
<ul>
<li>The Company's long-term financial framework includes expectations to deliver annually:
<ul>
<li>Organic NSR2 growth of 5% to 8%.</li>
<li>At least 20 to 30 basis points of adjusted EBITDA margin5 expansion.</li>
<li>At least 100% conversion of adjusted net income to free cash flow6.</li>
<li>Double-digit adjusted EPS1 and free cash flow6 per share growth.</li>
</ul>
</li>
<li>The Company also expects to achieve an at least 17% adjusted EBITDA margin5 exiting fiscal year 2025 and an at least 25% ROIC9 over the long term.</li>
</ul>

AECOM Long-term Financial Framework Includes Expectations To Deliver Annually: Organic NSR Growth Of 5%-8%; At Least 20 To 30 Basis Points Of Adjusted EBITDA Margin Expansion; At Least 100% Conversion Of Adjusted Net Income To Free Cash Flow; Double-Digit Adjusted EPS And Free Cash Flow Per Share Growth; Expects To Achieve An At Least 17% Adjusted EBITDA Margin Exiting Fiscal Year 2025 And An At Least 25% ROIC Over The Long Term

NWTN

NWTN Receives Delisting Determination Notice From Nasdaq

NRXP

NRx Pharmaceuticals Appoints Michael Abrams As CFO

General

CDRO

Codere Online Receives Delisting Notice From Nasdaq Due To Public Reports Rule; Co. Submits Appeal

Buybacks

AECOM Increases Share Repurchase Authorization To $1B

Dividends

AECOM Increases Quarterly Dividend From $0.22 To $0.26

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="4" rowspan="1">FY2025 GAAP EPS Guidance based on Adjusted EPS Guidance</td>
</tr>
<tr>
<td colspan="2" rowspan="1">(all figures approximate)</td>
<td colspan="1" rowspan="1">Fiscal Year End 2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP EPS guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$4.96 to $5.16</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS excludes:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of intangible assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.01</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of deferred financing fees</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.04</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax effect of the above items</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($0.01)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5.00 to $5.20</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">FY2025 GAAP Net Income from Continuing Operations Guidance based on Adjusted EBITDA Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(in millions, all figures approximate)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Fiscal Year End 2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP net income from continuing operations guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$724 to $743</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income attributable to noncontrolling interest from continuing operations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($60) to ($50)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income attributable to AECOM from continuing operations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$664 to $693</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net income attributable to AECOM from continuing operations excludes:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of intangible assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of deferred financing fees</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax effect of the above items</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($1) to ($2)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net income attributable to AECOM from continuing operations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$670 to $698</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA excludes:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$160</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted interest expense, net</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$129</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax expense, including tax effect of above items</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$211 to $223</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,170 to $1,210</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Note: Variances in tables are due to rounding.</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

AECOM Sees FY25 EPS $5.00-$5.20 Vs $5.02 Est.

Tuya (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUYA#NYSE">TUYA</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.03 by 33.33 percent. The company reported quarterly sales of $81.60 million which beat the analyst consensus estimate of $75.49 million by 8.09 percent. This is a 33.57 percent increase over sales of $61.09 million the same period last year.

Earnings Beats

Earnings Misses

TUYA

Tuya Q3 2024 Adj EPS $0.02 Misses $0.03 Estimate, Sales $81.60M Beat $75.49M Estimate

HCW Biologics reports Q2 results

Warning: HCWB is at high risk of performing badly

HCW Biologics reports Q3 results

HCW Biologics jumps on license agreement for immunotherapeutic product candidate

HCW Biologics (HCWB) and WY Biotech, a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell t...

HCW Biologics licenses proprietary preclinical molecule to WY Biotech

HCWB

Press Releases

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics and WY Biotech Announce License Agreement  for Immunotherapeutic Product Candidate

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

APLM

CRDL

NIVF

SINT

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Ensysce Biosciences

Imunon

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Mustang Bio

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NKGen Biotech

Nanoviricides

Onconetix

BiomX

PharmaCyte Biotech

Palatin Techs

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Senti Biosciences

Synlogic

Tenax Therapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

EF Hutton

JonesTrading

Maxim Group

HCW Biologics shares are trading higher after the company entered into an exclusive licensing deal with WY Biotech for immunotherapy development.

Comments

HCW Biologics

HCW Biologics (HCWB) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL